Latest Breaking News On - Serplulimab injection - Page 1 : comparemela.com

Fosun International Earns a Spot on 2024 Fortune China ESG Impact List

HONG KONG, May 15, 2024 /PRNewswire/ On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited was included in the list, highlighting its.

Ant groupWorld health organizationFosun international limitedNational medical products administrationFosun internationalFortune chinaChina pacific insuranceNew world chinaShui on landYum chinaUnited nations global compactGreater chinaHang seng corporate sustainability indexSustainability yearbookIndex seriesSerplulimab injection

Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure

/PRNewswire/ On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd. (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first.

United statesPei jin telpegfilgrastimWu yifangFosun pharmaHan si zhuangXin avatrombopagShanghai fosun pharmaceutical co ltd stock codeEuropean unionSinopharm group co ltdSeasonal malaria chemoprevention programSinopharm group coStock codeReporting periodSinopharm groupHan qu youMicrosatellite instability high

Fosun International : Pharma Announces 2023 Interim Results Continues to Promote Innovation Transformation and Optimizes Product Structure -Today at 06:26 am

Fosun Pharma Announces 2023 Interim Results Continues to Promote Innovation Transformation and Optimizes Product Structure Release.

United statesHan si zhuangWu yifangXin avatrombopagFosun pharmaPei jin telpegfilgrastimShanghai fosun pharmaceutical co ltd stock codeSeasonal malaria chemoprevention programSinopharm group coEuropean unionSinopharm group co ltdStock codeReporting periodSinopharm groupHan qu youMicrosatellite instability high

Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement

Performance Highlights: During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable. | March 28, 2023

United statesMacau generalHong kongFosun pharma artesunHan li kang rituximabGetz pharmaParsabiv etelcalcetideHan si zhuang serplulimabHan li kangFosun pharmaTridem pharmaWu yifangHan si zhuangNational medical insurance drug catalogueEuropean commissionNational reimbursement drug list

Börse Express - NDA für Henlius? neue Anti-PD-1-mAb Serplulimab zur Erstbehandlung von sqNSCLC von der chinesischen NMPA akzeptiert, MRCT der Phase III erreichte den primären Endpunkt

Börse Express - NDA für Henlius? neue Anti-PD-1-mAb Serplulimab zur Erstbehandlung von sqNSCLC von der chinesischen NMPA akzeptiert, MRCT der Phase III erreichte den primären Endpunkt
boerse-express.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-express.com Daily Mail and Mail on Sunday newspapers.

Jason zhuCaicun zhouDevelopment of productsExpress ndaChinese nmpaMrct reachedShanghai henliusNew drugCarboplatin andNational medicalSerplulimab injectionStudy resultsSerplulimab injection forShanghai pulmonary hospitalThe medicalMulti regional clinical